repeated transfusions are the mainstay of disease management in most patients with transfusion dependent beta thalassemia.iron overload predispose to oxidative stress and tissue injury. oxidative stress play important role in pathogenesis of anemia in beta thalassemia. vitamin E is often depleted in thalassemia patients.
oxidative stress status is very important in thalassemic patients and explains the different manifestations in thalassemic patients. vitamin E is fat soluble vitamin shown to reduce the oxidative stress in thalassemia and to reduce lipid peroxidation of red cell membranes. therefore, this study shows the safety of oral vitamin E as adjuvant therapy to three iron chelators : desferoxamine,deferiprone and deferasirox in moderately iron overloaded children and adolescents with transfusion dependent beta thalassemia and its relation to iron overload over one year.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
180
Vitamin E will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
placebo will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
Ain Shams University
Cairo, Abbasia, Egypt
effect of vitamin E on Liver iron concentration (LIC)
measuring the LIC using MRI (magnetic resonance imaging) in mg/g
Time frame: 12 months
effect of vitamin E on antioxidants enzymes
measuring antioxidants enzymes * antioxidant enzymes,
Time frame: 12 months
effect of vit E supplementation on SF
measuring serum ferritin(SF)in ng/ml
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.